What is Kybella®?
Kybella is an FDA-approved non-surgical injectable treatment used to treat the appearance and profile of moderate to severe fat below the chin (submental fat). It is not known if Kybella is safe and effective for use outside of the submental area.
How does Kybella work?
The active ingredient in Kybella is deoxycholic acid, a naturally-occurring molecule in the body that aids in the breakdown and absorption of dietary fat. When injected into the fat beneath your chin, Kybella causes the destruction of fat cells. Once destroyed, those cells cannot store or accumulate fat.
Our nurse injecting specialists will customize your Kybella treatment regimen, including how many treatments you need, based on your desired chin profile.
What should I expect after a Kybella treatment?
Swelling can take place from a few days to a week after the treatment session. Mild discomfort may be experienced at the injection sites. The most common side effects are swelling, bruising, pain, numbness, redness, and areas of hardness around the treatment area.
While Kybella offers a long-lasting solution, individuals may need more than one treatment to achieve their desired results. Our Aesthetic Nurse Specialists will examine your chin profile and the amount of submental fat to determine the right treatment plan for your needs.
If more treatments are needed, they are spaced 1 month or more apart to give ample time for the previous treatment to develop.
How long does Kybella last?
Once the fat cells have been broken down, they will be absorbed and eliminated through the body. Since the treated fat is gone, it is possible to enjoy long-lasting results.
However, if you do gain a significant amount of weight after Kybella treatment, the remaining fat cells can grow larger and cause the double chin to reappear. That is why maintaining a healthy lifestyle is important for maintaining your results
Kybella Next Steps
For more information on Kybella or to schedule your consultation, please call our office nearest you or contact us online.